Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.33% | 81,958.14% | 4.17% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.33% | 81,958.14% | 4.17% | 0.00% | 0.00% |
| Cost of Revenue | 28.83% | 24.73% | 54.16% | -13.93% | 86.63% |
| Gross Profit | -28.78% | 77.28% | -54.22% | 14.08% | -86.79% |
| SG&A Expenses | 116.07% | 68.81% | 25.83% | 13.83% | -52.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.36% | 32.33% | 47.86% | 67.84% | 22.35% |
| Operating Income | -44.33% | 52.07% | -47.90% | -67.93% | -22.38% |
| Income Before Tax | -50.96% | 54.88% | -54.99% | -79.04% | -19.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.96% | 54.88% | -54.99% | -79.04% | -19.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.96% | 54.88% | -54.99% | -79.04% | -19.24% |
| EBIT | -44.33% | 52.07% | -47.90% | -67.93% | -22.38% |
| EBITDA | -44.40% | 52.13% | -48.04% | -68.15% | -22.46% |
| EPS Basic | -32.98% | 61.07% | -29.72% | -46.86% | -867.91% |
| Normalized Basic EPS | -31.78% | 63.36% | -21.30% | -34.47% | 26.20% |
| EPS Diluted | -32.98% | 61.07% | -29.72% | -46.86% | -867.91% |
| Normalized Diluted EPS | -31.78% | 63.36% | -21.30% | -34.47% | 26.20% |
| Average Basic Shares Outstanding | 17.89% | 23.13% | 27.78% | 33.13% | 61.13% |
| Average Diluted Shares Outstanding | 17.89% | 23.13% | 27.78% | 33.13% | 61.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |